Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LCTX 
Lineage Cell Therapeutics Inc (LCTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: LCTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.17
1 Year Target Price $4.17
| 4 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -6.11% | Avg. Invested days 20 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 306.00M USD | Price to earnings Ratio - | 1Y Target Price 4.17 |
Price to earnings Ratio - | 1Y Target Price 4.17 | ||
Volume (30-day avg) 7 | Beta 1.67 | 52 Weeks Range 0.37 - 1.42 | Updated Date 09/13/2025 |
52 Weeks Range 0.37 - 1.42 | Updated Date 09/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.17 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -178.66% |
Management Effectiveness
Return on Assets (TTM) -13.17% | Return on Equity (TTM) -71.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 254445614 | Price to Sales(TTM) 28.04 |
Enterprise Value 254445614 | Price to Sales(TTM) 28.04 | ||
Enterprise Value to Revenue 23.31 | Enterprise Value to EBITDA -8.84 | Shares Outstanding 228356000 | Shares Floating 177830177 |
Shares Outstanding 228356000 | Shares Floating 177830177 | ||
Percent Insiders 0.42 | Percent Institutions 42.77 |
Upturn AI SWOT
Lineage Cell Therapeutics Inc
Company Overview
History and Background
Lineage Cell Therapeutics, Inc. was founded in 1999 as Geron BioMed Corporation and later renamed BioTime. BioTime then spun off Lineage Cell Therapeutics in 2019. The company focuses on developing allogeneic cell therapies for degenerative diseases.
Core Business Areas
- Ophthalmology: Focuses on developing cell therapies for age-related macular degeneration (AMD) and other retinal disorders. Their leading candidate is OpRegen.
- Spinal Cord Injury: Developing OPC1, an oligodendrocyte progenitor cell therapy for spinal cord injury.
- Oncology: Developing VAC2, an allogeneic cancer vaccine for non-small cell lung cancer.
Leadership and Structure
Brian M. Culley serves as the Chief Executive Officer. The company operates with a management team overseeing research, development, and clinical operations. The company has a Board of Directors.
Top Products and Market Share
Key Offerings
- OpRegen: A retinal pigment epithelium (RPE) cell therapy intended to treat the dry form of age-related macular degeneration (AMD). Currently in clinical development. Market share is not applicable since it is not approved and does not generate revenue. Competitors are IVERIC bio (ISEE) and Apellis Pharmaceuticals (APLS) which have FDA approved drugs to treat geographic atrophy secondary to AMD.
- OPC1: An oligodendrocyte progenitor cell therapy intended to treat spinal cord injury. Currently in clinical development. Market share is not applicable since it is not approved and does not generate revenue. No direct competitor with approved cell therapy drug.
- VAC2: An allogeneic cancer vaccine for non-small cell lung cancer. Currently in preclinical development. Market share is not applicable since it is not approved and does not generate revenue. Competitors are pharmaceutical companies with approved oncology therapies.
Market Dynamics
Industry Overview
The regenerative medicine industry is experiencing rapid growth, driven by advances in cell and gene therapies and a growing unmet medical need. Significant regulatory hurdles and high costs of development remain challenges.
Positioning
Lineage Cell Therapeutics is positioned as a clinical-stage biotechnology company focused on developing allogeneic cell therapies. Their competitive advantage lies in their proprietary cell therapy platform and clinical progress in targeting high unmet needs. Their success is dependent on regulatory approval and commercialization of their products.
Total Addressable Market (TAM)
The total addressable market for cell therapies in ophthalmology and spinal cord injury is substantial, potentially reaching billions of dollars annually. Lineage Cell Therapeutics is positioned to capture a portion of this market if its therapies are successfully developed and commercialized.
Upturn SWOT Analysis
Strengths
- Proprietary cell therapy platform
- Clinical-stage assets with promising early data
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Limited financial resources
- High risk associated with clinical development
- Dependence on successful clinical trial outcomes
- No products currently generating revenue
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Advancements in manufacturing technologies
Threats
- Regulatory setbacks
- Competition from other cell therapy companies
- Unfavorable changes in reimbursement policies
- Clinical trial failures
Competitors and Market Share
Key Competitors
- APLS
- ISEE
Competitive Landscape
Lineage is in a competitive landscape with many other companies. APLS & ISEE have approved therapies for Geographic Atrophy secondary to AMD. LCTX currently does not have any approved therpies to treat such illnesses.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by clinical trial progress and partnership agreements.
Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approvals for OpRegen, OPC1, and VAC2. Analyst projections vary widely, based on differing assumptions for success rates and market penetration.
Recent Initiatives: Recent initiatives include advancing clinical trials for OpRegen and OPC1 and pursuing strategic partnerships.
Summary
Lineage Cell Therapeutics is a clinical-stage biotechnology company focusing on allogeneic cell therapies. The company's strength lies in its promising clinical trial data and proprietary technology platform. However, it faces challenges related to limited financial resources, high clinical development risk, and reliance on positive trial outcomes. Success hinges on advancing therapies through clinical trials and securing regulatory approvals.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investing in biotechnology companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lineage Cell Therapeutics Inc
Exchange NYSE MKT | Headquaters Carlsbad, CA, United States | ||
IPO Launch date 1992-03-06 | CEO, President & Director Mr. Brian M. Culley M.A., M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 70 | Website https://www.lineagecell.com |
Full time employees 70 | Website https://www.lineagecell.com | ||
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a cell transplant program for an undisclosed indication through a gene editing collaboration, engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.